aiv infeqcia/SidsiT avadmyofTa mkurnaloba da movla (klinikuri ...
aiv infeqcia/SidsiT avadmyofTa mkurnaloba da movla (klinikuri ... aiv infeqcia/SidsiT avadmyofTa mkurnaloba da movla (klinikuri ...
122. Koval CE et al. Immune reconstitution syndrome after successful treatment of Pneumocystis carinii pneumonia in a man with human immunodeficiency virus type 1 infection. Clinical Infectious Diseases, 2002, 35(4):491–493. 123. Sande MA, Eliopoulos GM. The Sanford guide to HIV/AIDS therapy, 13th ed. Hyde Park, VT, Antimicrobial Therapy, 2004. 124. Gilbert DN, Moellering RC, Eliopoulos GM. The Sanford guide to antimicrobial therapy, 35th ed. Hyde Park, VT, Antimicrobial Therapy, 2005. 125. Antoniu T, Tseng AL. Interactions between recreational drugs and antiretroviral agents. The Annals of Pharmacotherapy, 2002, 36(10):1598–1613. 126. WHO/EURO report of the technical consultation on clinical staging of HIV/AIDS and HIV/AIDS case definition for surveillance. Copenhagen, WHO Regional Office for Europe, 2005 (http://www.euro. who.int/document/E87956.pdf, accessed 5 April 2006). 127. 2006 antiretroviral drug guide. IAPAC Monthly, 2006, 12 Suppl. 1 (http://www.iapac.org/home. asppid=7288, accessed 11 September 2006). 128. Liu H et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Annals of Internal Medicine, 2001, 134(10):968–977. 129. Bangsberg DR et al. Provider assessment of adherence to HIV antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 2001, 26(5):435–442. 130. Hugen PW et al. Assessment of adherence to HIV protease inhibitors: comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring. Journal of Acquired Immune Deficiency Syndromes, 2002, 30(3):324–334. 131. Paterson DL et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 2000, 133(1):21–30. 132. Parienti JJ et al. The pills identification test: a tool to assess adherence to antiretroviral therapy. JAMA, 2001, 285(4):412. 133. Descamps D et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. JAMA, 2000, 283(2):205–11. 134. Havlir DV et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavircontaining regimens. JAMA, 2000, 283(2):229–234. 135. Vingerhoets J et al. Effect of baseline resistance on the virologic response to a novel NNRTI, TMC 125, in patients with extensive NNRTI and PI resistance: analysis of study TMC 125–233. 13th Annual Conference on Retroviruses and Opportunistic Infections (CROI), Denver, 5–8 February 2006 (Abstract 154). 136. De Meyer et al. Effect of baseline susceptibility and on-treatment mutations on TMC 114 and control PI efficacy: preliminary analysis of data from PI-experienced patients from POWER 1 and POWER 2. 13th Annual Conference on Retroviruses and Opportunistic Infections (CROI), Denver, 5–8 February 2006 (Abstract 157). 72
Tavi II. oportunistuli infeqciebis marTva cxrili 19. oportunistuli infeqciebi da sxva daavadebebi, romlebic dakavSirebulia aiv infeqciasTan baqteriuli infeqciebi • tuberkulozi • baqteriuli respiratoru li infeqciebi • nawlavTa baqteriuli infeqciebi • atipiuri mikobaqterio zebi • bartonelozi sokovani infeqciebi • ezofaguri kandidozi • kriptokokozi • histoplazmozi • pnevmocisturi pnevmonia • kokcidioidozi virusuli infeqciebi • infeqciebi, romelsac iwvevs: _martivi herpes virusi; -varicelazosteris virusi - citomegalovirusi _adamianis herpes virusis 8 tipi; _adamianis papilomavirusi progresuli multifokaluri leikoencefalop aTia - hepatiti B da C parazituli infeqciebi • toqsoplazmozi • kriptosporidiozi • mikrosporidiozi • izosporiazi • leiSmaniozi sxva daavadebebi • kapoSis sarkoma • arahojkinsis limfoma • saSvilosnos yelis simsivne • encefalopaTia • vakuoluri mielopaTia evropis regionisTvis yvelaze xSiri oportunistuli infeqciebia: o tuberkulozi o baqteriuli infeqciebi o pnevmocisturi pnevmonia o herpesuli infeqciebi (VZV, HSV 1 da 2, CMV) o kandidozuri ezofagiti o kriptokokuli meningiti o toqsoplazmozi SederebiT iSviaT oportonistul infeqciebs da simsivneebs miekuTvneba; o atipiuri mikobaqteriozebi o kapoSis sarkoma o arahojkinis limfoma o citomegalovirusuli infeqciebi (retina, kuW-nawlavis traqti, encefalitebi). cxrili 2. oportunistuli infeqciebis profilaqtika aiv inficirebul pacientebSi gamomwvevi maCveneblebi pirveli rigis preparatebi Pneumocystis CD4< 200mkl-1 ko-tromoqsazoli jirovecii an 160/800 mg/dReSi yovel orofaringeuli Aalternatiuli sqemebi - ko-tromoqsazoli 80-400 mg/dReSi 73
- Page 21 and 22: SeuZlebelia da gadamwyveti misi dia
- Page 23 and 24: persistuli generalizebuli limfadeno
- Page 25 and 26: signalis amplifikacia komplementuri
- Page 27 and 28: • vizitamde rezistentobis testis
- Page 29 and 30: • adamianis papilomavirusi (maxvi
- Page 31 and 32: etinitis identifikaciisTvis, rodesa
- Page 33 and 34: cxrili 8 rekomendaciebi arT dawyebi
- Page 35 and 36: arv medikamentebi arseboben Semdegi
- Page 37 and 38: aCveneben, rom pirveladi rezistento
- Page 39 and 40: - tabletebis Cveneba pacientisTvis
- Page 41 and 42: - aqedan gamomdinare, nrti+anrti re
- Page 43 and 44: igulisxmeba im medikamentebis kombi
- Page 45 and 46: X (arv): testebi, romlebic unda Cat
- Page 47 and 48: maRali mgrZnobeloba abakaviri (ABC
- Page 49 and 50: transaminazebis elevacia anrti (all
- Page 51 and 52: ARV toqsiuroba menejmenti nefrotoqs
- Page 53 and 54: xSiri oportonistuli infeqciebia, ma
- Page 55 and 56: cxrilebis wakiTxvis magaliTi 1. cxr
- Page 57 and 58: damateba2. jandacvis msoflio organi
- Page 59 and 60: damateba 4. ZiriTadi informacia ant
- Page 62 and 63: damateba 5. mkurnalobis reJimis dac
- Page 64 and 65: saerTaSoriso saxeli stavudini (d4T)
- Page 66 and 67: mcire mutacia muSaobs kombinaciaSi.
- Page 68 and 69: 25. Phillips AN et al. Viral load o
- Page 70 and 71: Suppl 2:S171-176. 73. Altice FL, Mo
- Page 74 and 75: kandidozi dRe yovel dRe - ko-trimoq
- Page 76 and 77: karcinoma (ara SidsTan perikardiuli
- Page 78 and 79: o cxeleba o wonaSi kleba o Ramis of
- Page 80 and 81: indikatorebi filtvis darRveuli funq
- Page 82 and 83: o yvelaze xSirad viTardeba diarea,
- Page 84 and 85: o glukokortikoidebis sistematiuri m
- Page 86 and 87: 100 mg/dReSi meore rigis sqemebi am
- Page 88 and 89: o eqspoziciis Sedegad daavadebis ga
- Page 90 and 91: o remisiis miRweva Zalian Znelia da
- Page 92 and 93: qimioTerapiiT (mag : B-ALL reJimi)
- Page 94 and 95: • imunodeficitis mqone pacientebS
- Page 96 and 97: an famcikloviri 500 mg 3-jer dReSi
- Page 98 and 99: • berkitis-tipis limfoma; • naz
- Page 100 and 101: 3.2.2. cxeleba aiv inficirebulebSi
- Page 102 and 103: afTozuri wylulebi stomatiti qeiliti
- Page 104 and 105: ganmavlobaSi 2 Tvis manZilze (xelis
- Page 106 and 107: o gamonayari warmodgenilia mravlobi
- Page 108 and 109: 20. Chen XM et al. Cryptosporidiosi
- Page 110 and 111: Tavi IV. aiv infeqcia/SidsiT daavad
- Page 112 and 113: inficirebul bavSvebSi (ramdenadac a
- Page 114 and 115: 8 igulisxmeba piri, romelsac aReniS
- Page 116 and 117: 4.3. daxocili da inaqtivirebuli vaq
- Page 118 and 119: kerebSi A hepatiti erTeuli an mcire
- Page 120 and 121: 13 riski maRalia staJirebis periodS
Tavi II. oportunistuli infeqciebis marTva<br />
cxrili 19. oportunistuli infeqciebi <strong>da</strong> sxva <strong>da</strong>avadebebi, romlebic<br />
<strong>da</strong>kavSirebulia <strong>aiv</strong> <strong>infeqcia</strong>sTan<br />
baqteriuli<br />
infeqciebi<br />
• tuberkulozi<br />
• baqteriuli<br />
respiratoru<br />
li<br />
infeqciebi<br />
• nawlavTa<br />
baqteriuli<br />
infeqciebi<br />
• atipiuri<br />
mikobaqterio<br />
zebi<br />
• bartonelozi<br />
sokovani<br />
infeqciebi<br />
• ezofaguri<br />
kandidozi<br />
• kriptokokozi<br />
• histoplazmozi<br />
• pnevmocisturi<br />
pnevmonia<br />
• kokcidioidozi<br />
virusuli<br />
infeqciebi<br />
• infeqciebi,<br />
romelsac<br />
iwvevs:<br />
_martivi herpes<br />
virusi;<br />
-varicelazosteris<br />
virusi<br />
- citomegalovirusi<br />
_a<strong>da</strong>mianis<br />
herpes virusis 8<br />
tipi;<br />
_a<strong>da</strong>mianis<br />
papilomavirusi<br />
progresuli<br />
multifokaluri<br />
leikoencefalop<br />
aTia<br />
- hepatiti B <strong>da</strong><br />
C<br />
parazituli<br />
infeqciebi<br />
• toqsoplazmozi<br />
• kriptosporidiozi<br />
• mikrosporidiozi<br />
• izosporiazi<br />
• leiSmaniozi<br />
sxva<br />
<strong>da</strong>avadebebi<br />
• kapoSis<br />
sarkoma<br />
• arahojkinsis<br />
limfoma<br />
• saSvilosnos<br />
yelis simsivne<br />
• encefalopaTia<br />
• vakuoluri<br />
mielopaTia<br />
evropis regionisTvis yvelaze xSiri oportunistuli infeqciebia:<br />
o tuberkulozi<br />
o baqteriuli infeqciebi<br />
o pnevmocisturi pnevmonia<br />
o herpesuli infeqciebi (VZV, HSV 1 <strong>da</strong> 2, CMV)<br />
o kandidozuri ezofagiti<br />
o kriptokokuli meningiti<br />
o toqsoplazmozi<br />
SederebiT iSviaT oportonistul infeqciebs <strong>da</strong> simsivneebs miekuTvneba;<br />
o atipiuri mikobaqteriozebi<br />
o kapoSis sarkoma<br />
o arahojkinis limfoma<br />
o citomegalovirusuli infeqciebi (retina, kuW-nawlavis traqti,<br />
encefalitebi).<br />
cxrili 2. oportunistuli infeqciebis profilaqtika <strong>aiv</strong> inficirebul<br />
pacientebSi<br />
gamomwvevi maCveneblebi pirveli rigis<br />
preparatebi<br />
Pneumocystis CD4< 200mkl-1 ko-tromoqsazoli<br />
jirovecii<br />
an<br />
160/800 mg/dReSi yovel<br />
orofaringeuli<br />
Aalternatiuli<br />
sqemebi<br />
- ko-tromoqsazoli<br />
80-400 mg/dReSi<br />
73
Change language